Every material Form 8-K HCW Biologics Inc. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
HCW Biologics entered into a notes purchase agreement with Streeterville Capital on November 3, 2026, and closed the financing on November 4, 2026. The company received $3.0 million at closing, with a further $7.0 million held in a controlled account subject to conditions, and says it will use the proceeds for clinical development, business development and general corporate purposes. The notes are secured and carry lender redemption rights, default triggers and a 10% prepayment premium, which shareholders should weigh against the added funding.
$3.0 million received at closing on November 4, 2026, after $30,000 in transaction costs; a further $7.0 million is deposited in a controlled account subject to conditions
Promissory Note A-1 of $3.2 million includes a $240,000 original issue discount; Note B of $7.0 million carries no discount; both are due in 24 months, at 8% and 5% interest per annum
Beginning six months after closing, the lender may redeem up to $125,000 per calendar month on the A-1 Note; the notes are secured by a controlled account, a subsidiary guaranty and a pledge of subsidiary membership interests
Maxim Group LLC, the placement agent, is to receive a cash fee of 7.0% of gross proceeds
On September 23, 2026, HCW Biologics agreed to sell 903,614 units to an existing institutional investor for approximately $1.5 million in gross proceeds before offering expenses. Each unit pairs a pre-funded warrant with the right to receive a common warrant at $1.66 per share, which is issuable only after stockholder approval that the company is obligated to seek. The company plans to use the proceeds for working capital, clinical development and general corporate purposes, and it agreed to register the resale of the shares underlying the warrants, which could add shares to the market.
903,614 units sold at $1.6599 per unit; pre-funded warrants have a $0.0001 exercise price
Common warrants for up to 903,614 shares, exercisable at $1.66 per share for 5.5 years after issuance, subject to stockholder approval under Nasdaq Rule 5635(d)
Maxim Group LLC is the sole placement agent
Company must file a resale registration statement within 15 trading days after closing and use commercially reasonable efforts to have it declared effective within 60 days
HCW Biologics filed an amended preliminary proxy statement on September 9, 2026, after the board decided not to seek stockholder approval of Proposal No. 2, an amended performance-based equity plan for eligible officers, directors and employees. The amendment also changes the Special Meeting date, the record date and certain other dates.
Proposal No. 2, an amended performance-based equity plan, was removed from the proxy after stockholder feedback.
The amendment changes the date of the Special Meeting of Stockholders and the record date.
The original preliminary proxy statement was filed with the SEC on September 8, 2026.
No other substantive changes were made to the original preliminary proxy statement, per the filing.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HCW Biologics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →